NCT05273528 - The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

January 6, 2023

Study Completion Date

January 6, 2023

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL

Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Trial Locations (1)

Shaoguan Hospital of Chinese Medicine, Shaoguan